CibusCBUS
CBUS
About: Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
Employees: 159
0
Funds holding %
of 7,321 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
900% more call options, than puts
Call options by funds: $10K | Put options by funds: $1K
53% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 15
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
0.89% more ownership
Funds ownership: 35.78% [Q4 2024] → 36.67% (+0.89%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]
1% less funds holding
Funds holding: 68 [Q4 2024] → 67 (-1) [Q1 2025]
15% less capital invested
Capital invested by funds: $26.5M [Q4 2024] → $22.5M (-$3.99M) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$17.50
942%
upside
Avg. target
$17.50
942%
upside
High target
$17.50
942%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Canaccord Genuity Austin Moeller | 942%upside $17.50 | Buy Maintained | 12 May 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
3 weeks ago
The U.S. Food and Drug Administration Completes Review of Cibus' Altered Lignin Alfalfa Developed in Partnership with S&W Seed Company for use in Livestock Feed
SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company”), a leading agricultural technology company that develops and licenses plant traits to seed companies, announced today that it has completed the U.S. Food and Drug Administration's (FDA) Plant Biotechnology Consultation Program for its altered lignin alfalfa trait with the FDA notifying Cibus that it has no further questions concerning the use of altered lignin alfalfa in food or feed. To develop altered lignin alfalfa, Cibus (formerly Calyxt, Inc.) collaborated with S&W Seed Company to identify an alfalfa trait with an altered lignin profile providing potential increased nutrient availability for livestock.
Neutral
GlobeNewsWire
1 month ago
Cibus and John Innes Centre Announce Ongoing Collaboration with Potential to Revolutionize Fertilizer Use in Farming
Researchers at the John Innes Centre (JIC) have discovered a genetic mutation with the potential to enhance nutrient uptake and reduce the need for artificial fertilizers Cibus and JIC have agreed on a collaboration with the potential to introduce the trait into several commercial crops Cibus previously announced the successful editing of Canola plants with this mutation and looks forward to further testing and trait validation SAN DIEGO, June 12, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. ("Cibus" or the "Company") (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today confirmed its continuing collaboration with the John Innes Centre (JIC). Cibus applauds the JIC breakthrough discovery, published earlier this year in the journal Nature, of a biological mechanism that makes plant roots more welcoming to beneficial soil microbes.
Neutral
GlobeNewsWire
1 month ago
Cibus, Inc. Announces Closing of $27.5 Million Public Offering
SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced the closing of its previously announced public offering of 15,714,285 shares of its Class A Common Stock, at a purchase price of $1.75 per share, including to institutional and strategic investors, as well as the Chairman of Cibus' board of directors (5,714,286 shares).
Neutral
GlobeNewsWire
1 month ago
USDA Designates Cibus' Herbicide Tolerance Canola Trait HT2 as Not Regulated Under USDA's Biotechnology Regulations
This action follows the USDA's recent designation of Cibus' disease resistance traits in Canola as not regulated, continuing Cibus' product development momentum in the globally important Canola crop This action follows the USDA's recent designation of Cibus' disease resistance traits in Canola as not regulated, continuing Cibus' product development momentum in the globally important Canola crop
Neutral
GlobeNewsWire
1 month ago
Cibus, Inc. Announces Pricing of $27.5 Million Public Offering
SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced the pricing of its previously announced public offering of 15,714,285 shares of its Class A Common Stock, at a purchase price of $1.75 per share, including to institutional and strategic investors, as well as the Chairman of Cibus' board of directors (5,714,286 shares).
Neutral
GlobeNewsWire
1 month ago
Cibus, Inc. Announces Proposed Public Offering
SAN DIEGO, June 04, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that it intends to offer shares of its Class A common stock (or common stock equivalents in lieu thereof) in a public offering. All of the securities to be sold in the offering are to be offered by Cibus. The Chairman of Cibus' board of directors, Mr. Rory Riggs, has indicated an interest in purchasing up to $10.0 million of shares of Class A common stock and/or common stock equivalents in this offering. Because such an indication of interest is not a binding agreement or commitment to purchase, Mr. Riggs may elect not to purchase any shares in this offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Neutral
GlobeNewsWire
1 month ago
Cibus Provides Webcast of BofA Securities AgTech Virtual Conference Fireside Chat
SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the "Company"), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that Peter Beetham, Co-Founder, President and Interim Chief Executive Officer, participated in the BofA Securities 2025 AgTech Virtual Conference this week.
Neutral
GlobeNewsWire
2 months ago
Cibus to Participate in Alliance Global Partner's Annual Virtual Healthcare Company Showcase
SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the "Company"), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that Peter Beetham, Co-Founder, President, and Interim Chief Executive Officer, will host a presentation at the AGP Annual Virtual Healthcare Company Showcase. During the presentation, Dr. Beetham will discuss the Company's progress in advancing its gene-editing technology platform, recent regulatory developments supporting agricultural innovation, and Cibus' commercialization strategy for its productivity trait pipeline.
Neutral
Seeking Alpha
2 months ago
Cibus, Inc. (CBUS) Q1 2025 Earnings Call Transcript
Cibus, Inc. (NASDAQ:CBUS ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Carlo Broos - Interim CFO Peter Beetham - Co-Founder, Interim CEO, President, COO & Director Gregory Gocal - Co-Founder, Chief Scientific Officer & EVP Conference Call Participants Laurence Alexander - Jefferies Austin Moeller - Canaccord Sameer Joshi - H.C. Wainwright Matthew Venezia - AGP Operator Good afternoon, and welcome to the Cibus 1Q '25 Earnings Call.
Negative
Zacks Investment Research
2 months ago
Cibus (CBUS) Reports Q1 Loss, Misses Revenue Estimates
Cibus (CBUS) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $1.12 per share a year ago.
Charts implemented using Lightweight Charts™